Two-stage nanoparticle delivery of piperlongumine and TRAIL anti-cancer therapy

May 20, 2016, World Scientific Publishing
Piperlongumine (PL) was encapsulated in PLGA polymer nanoparticles. TRAIL was chemically conjugated to the surface of liposomes. Credit: World Scientific Publishing

A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents.

The mechanism was utilized to deliver a new anti-cancer combination therapy consisting of piperlongumine (PL) and TRAIL to treat PC3 prostate cancer and HCT116 colon . PL, a small-molecule hydrophobic drug, was encapsulated in poly (lactic-co-glycolic acid) (PLGA) nanoparticles. TRAIL was chemically conjugated to the surface of nanoscale liposomes. PL was first administered to sensitize cancer to the effects of TRAIL. PC3 and HCT116 cells had lower survival rates in vitro after receiving the dual nanoparticle therapy compared to each agent individually. In vivo testing involved a subcutaneous mouse xenograft model using NOD-SCID gamma mice and HCT116 cells. Two treatment cycles were administered over 48 hours. Higher apoptotic rates were observed for HCT116 that received the dual nanoparticle therapy compared to individual stages of the nanoparticle therapy alone. The report appears in the latest issue of the journal Technology.

"We have found that liposomal TRAIL shows great promise for the destruction of tumor cells in the bloodstream, lymphatic system, and also in solid tumors," says Daljit S. and Elaine Sarkaria Professor Michael R. King, Ph.D., of Cornell University and senior author of the study.

In the paper, the Cornell researchers describe a nanoparticle-based drug delivery mechanism developed for a combination cancer therapy. Nanoparticle delivery platforms have been previously pursued for a variety of cancer therapies. A number of studies have focused on complex particle structures and designs aimed at improving delivery. The Cornell group's system utilizes a different approach through the use of a dual nanoparticle delivery mechanism. Therapeutic components were administered through separate particles as opposed to delivering the agents in a single particle. Given the hydrophobic nature of the TRAIL sensitizer, the drug was encapsulated in polymer-based nanoparticles.

In the study, researchers observed of a higher number of apoptotic cells in mouse trials, consistent with their observed laboratory results that demonstrated an increased therapeutic efficacy when utilizing the two-stage nanoparticle therapy compared to each individual nanoparticle stage alone. The dual nanoparticle delivery system provided a level of flexibility when administering the two stages of the therapy, allowing for an opportunity for sensitization of the tumor cells prior to administering the second component of the therapy.

The team from Cornell is working now to develop a new therapeutic approach to target cancer cells in the bloodstream for the prevention of prostate cancer metastasis, that utilizes circulating leukocytes as a carrier for the apoptosis ligand TRAIL. Once introduced into the bloodstream, E-selectin/TRAIL liposomes attach to the surface of peripheral blood leukocytes, to render these "unnatural killer cells" cytotoxic to circulating cancer cells without affecting blood cell or endothelial cell viability. They previously showed that viable cancer cells can be rapidly cleared from the bloodstream, using liposome-bound TRAIL concentrations that are two orders of magnitude lower than the dosages used in prior human clinical trials of soluble TRAIL protein. More recently, they have found that E-selectin/TRAIL liposomes can completely block metastasis and also shrink primary prostate cancer tumors in mice.

Explore further: Cancer-killing proteins destroy tumor cells in bloodstream

More information: Charles C. Sharkey et al. Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy, TECHNOLOGY (2016). DOI: 10.1142/S2339547816500011

Related Stories

Cancer-killing proteins destroy tumor cells in bloodstream

January 12, 2016

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. ...

Researchers disguise drugs as platelets to target cancer

September 29, 2015

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and ...

Recommended for you

Engineers produce smallest 3-D transistor yet

December 10, 2018

Researchers from MIT and the University of Colorado have fabricated a 3-D transistor that's less than half the size of today's smallest commercial models. To do so, they developed a novel microfabrication technique that modifies ...

New traffic rules in 'Graphene City'

December 6, 2018

In the drive to find new ways to extend electronics beyond the use of silicon, physicists are experimenting with other properties of electrons, beyond charge. In work published today (Dec 7) in the journal Science, a team ...

Artificial synapses made from nanowires

December 6, 2018

Scientists from Jülich together with colleagues from Aachen and Turin have produced a memristive element made from nanowires that functions in much the same way as a biological nerve cell. The component is able to save and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.